FDA Peptide Reclassification 2026: What It Means for Providers The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Peptides and BPC 157 for Pain: What's the deal? fda warning bpc 157 peptide products New Details 157